Detalhe da pesquisa
1.
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Breast Cancer Res Treat
; 199(2): 243-252, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36944848
2.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med
; 380(7): 617-628, 2019 02 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30516102
3.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 555-564, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35230585
4.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33460574
5.
A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
Breast Cancer Res Treat
; 187(3): 777-784, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-33740205
6.
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Cancer
; 126(13): 3132-3139, 2020 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32286687
7.
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Lancet
; 394(10215): 2155-2164, 2019 12 14.
Artigo
Inglês
| MEDLINE | ID: mdl-31813636
8.
Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles.
Ann Surg Oncol
; 27(7): 2269-2275, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-32318946
9.
Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers.
Lancet Oncol
; 20(7): e390-e396, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31267973
10.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(1): 88-99, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30509771
11.
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Breast Cancer Res Treat
; 178(2): 389-399, 2019 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-31428908
12.
Metaplastic breast carcinoma: Current therapeutic approaches and novel targeted therapies.
Breast J
; 25(6): 1192-1197, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31250492
13.
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.
Cancer
; 124(14): 2923-2930, 2018 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29723396
14.
Current approach of the axilla in patients with early-stage breast cancer.
Lancet
; 2017 Aug 14.
Artigo
Inglês
| MEDLINE | ID: mdl-28818521
15.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Breast Cancer Res Treat
; 168(1): 69-77, 2018 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-29128898
16.
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 387(10021): 849-56, 2016 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-26686957
17.
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 387(10021): 857-65, 2016 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-26686960
18.
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 565, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35507135
19.
Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
Ann Surg Oncol
; 29(11): 6504-6507, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35717518
20.
Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy.
Ann Surg Oncol
; 24(2): 375-397, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27933411